Department of Therapeutic Radiology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.
Department for Medical Statistics, Medical University of Innsbruck, Innsbruck, Austria.
Sci Rep. 2021 Apr 21;11(1):8639. doi: 10.1038/s41598-021-88070-5.
Overall survival (OS) of patients with brain metastases treated with hypofractionated (HFSRT) or single-fraction (SRS) radiosurgery depends on several prognostic factors. The aim of this study was to investigate the potential of sex as an independent predictor of OS and evaluate the predictive accuracy of common prognostic scores. Retrospective analysis of 281 consecutive patients receiving radiosurgery of brain metastases was performed. Kaplan-Meier survival curves and Cox proportional hazards models were used to compare OS between SRS and HFSRT and by sex, before and after propensity-score matching (PSM) on key baseline prognostic covariates. Prognostic scores were evaluated using Harrell's concordance index. Median OS was 11 months after both SRS and HFSRT. After PSM, median OS was 12 months after SRS (95% CI: 7.5-16.5) and 9 months after HFSRT (95% CI: 5.0-13.0; p = 0.77). Independent prognostic factors were sex, primary tumor, KPI, and systemic disease status. Median OS was 16 months for women and 7 months for male patients (p < 0.001). After excluding sex specific tumors, PSM revealed a median OS of 16 months for women and 8 months for male patients (p < 0.01). Evaluation of prognostic indices showed BSBM to be the most accurate (Harrell's C = 0.68), followed by SIR (0.61), GPA (0.60), RPA (0.58), and Rades et al. (0.57). OS after HFSRT and SRS did not differ, although PSM revealed a non-significant advantage for SRS. Female sex was found to be a major independent positive prognostic factor for survival, and thus should be considered in the personalized decision-making of brain metastases treatment.
脑转移瘤患者接受立体定向放射外科治疗(SRS)或大分割立体定向放射治疗(HFSRT)后的总生存(OS)取决于多个预后因素。本研究旨在探讨性别是否为 OS 的独立预测因素,并评估常见预后评分的预测准确性。对 281 例连续接受脑转移瘤放射外科治疗的患者进行回顾性分析。使用 Kaplan-Meier 生存曲线和 Cox 比例风险模型比较 SRS 和 HFSRT 之间以及按性别比较 OS,在对关键基线预后协变量进行倾向评分匹配(PSM)之前和之后。使用 Harrell 的一致性指数评估预后评分。SRS 和 HFSRT 后中位 OS 分别为 11 个月和 9 个月。PSM 后,SRS 后中位 OS 为 12 个月(95%CI:7.5-16.5),HFSRT 后为 9 个月(95%CI:5.0-13.0;p = 0.77)。独立的预后因素为性别、原发肿瘤、KPI 和全身疾病状态。女性患者的中位 OS 为 16 个月,男性患者为 7 个月(p<0.001)。排除性别特异性肿瘤后,PSM 显示女性患者的中位 OS 为 16 个月,男性患者为 8 个月(p<0.01)。对预后指数的评估显示 BSBM 最准确(Harrell 的 C=0.68),其次是 SIR(0.61)、GPA(0.60)、RPA(0.58)和 Rades 等人(0.57)。HFSRT 和 SRS 后的 OS 没有差异,尽管 PSM 显示 SRS 有非显著性优势。女性被发现是生存的一个主要独立的正预后因素,因此在脑转移瘤治疗的个体化决策中应考虑到这一点。